SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TELUS Corp. is a telecommunications company, which engages in the provision of telecommunication services and products primarily for wireless and wireline voice and data. It operates through TELUS Technology Solutions (TTech) and Digitally-led Customer Experiences–TELUS International (DLCX) segments. The TTech segment includes network revenues and equipment sales arising from mobile technologies, data revenues, healthcare software and technology solutions, voice and other telecommunications services revenues, and equipment sales. The DLCX segment is composed of digital customer experience and digital-enablement transformation solutions, including artificial intelligence and content management solutions, provided by TELUS International. The company was founded on October 4, 1990 and is headquartered in Vancouver, Canada.

Telus Corp.

TELUSs reported results and roughly halving of its dividend to support debt reduction have driven sharp selling and concern about its outlook. Bears question management, debt levels and its AI strategy, while some income-focused investors see the selloff as an opportunity to accumulate.

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

SHIB is drawing attention amid a modest uptick after a prolonged stretch of sideways, choppy trading. Some traders see signs of a potential breakout and hope for a broader meme-coin rally, while others are frustrated by the lack of sustained momentum and question the tokens utility and large supply.

Select Sector SPDR Trust (The) - State Street Financial Select Sector SPDR ETF

Financial Select Sector SPDR Fund

XLF is drawing attention amid a sharp, volatile pullback in financial stocks, with elevated Treasury yields and rate concerns weighing on the sector as major banks approach earnings. Traders are divided between an oversold bounce or rotation back into banks and the risk of further declines if earnings disappoint or technical support fails.

T-Mobile US, Inc. engages in the provision of wireless communications services under the T-Mobile and MetroPCS brands. It offers postpaid and prepaid wireless voice, messaging and data services, and wholesale wireless services. The company was founded in 1994 and is headquartered in Bellevue, WA.

T-Mobile US Inc

SpaceXs spectrum acquisition and Starlink Mobile ambitions have raised fears that it could become a new wireless competitor, weighing on T-Mobile and other carriers. Traders disagree on whether the selloff overstates the threatciting the time and infrastructure needed to build a competitive networkor reflects a meaningful long-term challenge.

Citigroup, Inc. is a holding company, which engages in the provision of financial products and services. It operates through the following segments: Services, Markets, Banking, Wealth, U.S. Personal Banking (USPB), and All Other. The Services segment includes Treasury and Trade Solutions (TTS) which provides an integrated suite of tailored cash management, trade, and working capital solutions to multinational corporations, financial institutions and public sector organizations, and Securities Services, which offers cross-border support for clients, providing on-the-ground local market expertise, post-trade technologies, customized data solutions, and a wide range of securities services solutions that can be tailored to meet client needs. The Markets segment provides corporate, institutional, and public sector clients around the world with a full range of sales and trading services across equities, foreign exchange, rates, spread products, and commodities. The Banking segment offers Investment Banking and Corporate Lending services. The Wealth segment includes Private Bank, Wealth at Work, and Citigold and provides financial services to a range of client segments through banking, lending, mortgages, investment, custody, and trust product offerings. The USPB segment includes Branded Cards and Retail Services, which have proprietary card portfolios and co-branded card portfolios within Branded Cards, and co-brand and private label relationships within Retail Services. The All Other segment consists of activities not assigned to the reportable operating segments, including certain unallocated costs of global functions, other corporate expenses, and net treasury results. The company was founded in 1812 and is headquartered in New York, NY.

Citigroup Inc

Citigroup is drawing attention ahead of Q3 bank earnings, with traders weighing whether results and guidance can overcome pressure on bank stocks from rising yields and concerns about lending and credit quality. Some expect a miss or weaker outlook, while others are buying the pullback and pointing to bullish options activity.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

A suspected pneumonic-plague incident at a Russian research institute has renewed interest in EBS as a biodefense play, with traders speculating about government demand and a possible short-covering rally. Others remain cautious, pointing to earnings concerns and refinancing risk; the outbreaks implications for EBS contracts are not confirmed.

Subsquid Network is an innovative decentralized data lake and query engine designed to offer developers performant and permissionless access to data, aiming to build a neutral and open internet rooted in Web3 principles. Secured by ZK proofs, the Subsquid network boasts a modular architecture that enables exceptional scalability and developer convenience optimized for blockchain indexing, dApp development, and analytics.  Subsquid is a response to unscalable and rigid monolithic indexing frameworks that had previously gained popularity and market traction among Web3 developers. Today, these frameworks are struggling to adapt in a rapidly evolving blockchain environment. Additionally, the network serves as a highly efficient and decentralized alternative to centralized infrastructure firms, including large RPC and API providers.

Attention centers on SQDs blockchain-data infrastructure and reported Google Cloud, Robinhood and Solana connections, with traders anticipating further enterprise adoption as tokenization grows. Bullish holders see these integrations as validation, while skeptics question whether network usage will translate into token value; talk of a buyback or another Google partnership remains speculative.

e.l.f. Beauty, Inc. is a holding company, which engages in the provision of inclusive, accessible, clean, vegan and cruelty free cosmetics and skin care products. The company focuses on the e-commerce, national retailers and international business channels. Its brands include elf, elf skin, naturium, well people, and keys soulcare. The company was founded in 2004 and is headquartered in Oakland, CA.

e.l.f. Beauty Inc

e.l.f. Beautys stronger-than-expected quarterly results and raised outlook, alongside optimism about Rhodes international rollout and brand momentum, are fueling attention. Bulls see room for continued growth, while skeptics point to rising marketing costs, a rich valuation, and profit-taking after the stocks rebound.

RTX Corp. is an aerospace and defense company, which engages in the provision of aerospace and defense systems and services for commercial, military, and government customers. It operates through the following segments: Collins Aerospace Systems (Collins), Pratt and Whitney, Raytheon Intelligence and Space (RIS), and Raytheon Missiles and Defense (RMD). The Collins segment manufactures and sells aero structures, avionics, interiors, mechanical systems, mission systems, and power controls. The Pratt and Whitney segment includes the design and manufacture of aircraft engines and auxiliary power systems for commercial, military, and business aircraft. The RIS segment is involved in the development of sensors, training, and cyber and software solutions. The RMD segment offers end-to-end solutions to detect, track, and engage threats. The company was founded in 1922 and is headquartered in Arlington, VA.

RTX Corp

Raytheon Technologies Corporation

Raytheons multiyear U.S. Navy contract for SM-3 interceptors is drawing attention as part of a broader push to replenish missile-defense inventories. Traders view the award as supportive of demand and backlog, but many are frustrated by RTXs weak share performance and flag uncertainty over congressional funding.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

Johnson & Johnsons upcoming quarterly report is drawing attention, with traders weighing its raised annual outlook and drug pipeline against concern about recent share weakness. Separately, some traders speculate J&J could acquire Sellas Life Sciences ahead of its REGAL trial results, but no deal is confirmed.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Analysts See a 145.35% Upside in Eupraxia Pharmaceuticals Inc. (EPRX): Can the Stock Really Move This High?

The consensus price target hints at a 145.4% upside potential for Eupraxia Pharmaceuticals Inc. (EPRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Eupraxia Pharmaceuticals' (EPRX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated a "buy" rating and issued a $11.00 price objective on shares of Eupraxia Pharmaceuticals in a research report on Monday...

Eupraxia Pharmaceuticals (EPRX) to Release Quarterly Earnings on Wednesday

Eupraxia Pharmaceuticals (NASDAQ:EPRX) will be releasing earnings before the market opens on Wednesday, May 6. (View Earnings Report at...

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Average Recommendation of "Moderate Buy" by Analysts

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eight brokerages that are covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, four have given a buy re...

Eupraxia Pharmaceuticals (NASDAQ:EPRX) Receives Buy Rating from HC Wainwright

HC Wainwright reissued a "buy" rating and issued a $11.00 target price on shares of Eupraxia Pharmaceuticals in a report on Wednesday...

Eupraxia Pharmaceuticals (NASDAQ:EPRX) Raised to "Sell" at Wall Street Zen

Wall Street Zen raised Eupraxia Pharmaceuticals from a "strong sell" rating to a "sell" rating in a report on Saturday...

New Strong Sell Stocks for April 2nd

ACCO, CDE and EPRX have been added to the Zacks Rank #5 (Strong Sell) List on April 2nd, 2026.

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Short Interest Up 26.3% in March

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Get Free Report) was the target of a large increase in short interest during the month of March. As of March 13th, there was short interest totaling 2,500,950 shares, an increase of 26.3% from the February 26th total of 1,979,996 shares. Approximately...

Eupraxia Pharmaceuticals (EPRX) to Release Earnings on Tuesday

Eupraxia Pharmaceuticals (NASDAQ:EPRX) will be releasing earnings before the market opens on Tuesday, March 31. (View Earnings Report at...

Eupraxia Pharmaceuticals Boasts $900 Million Peak Sales Potential: Analyst

William Blair starts Eupraxia at Outperform as the analyst flags unmet need and sizable market potential.read more...

Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. It delivers drugs into body compartments, such as the joint without any of the common issues with body compartment injections, such as systemic exposure. The firm focuses on arthritis, diabetic macular edema, and chronic pain programs. The company was founded by James A. Helliwell, John Salvatore Montalbano and Amanda Malone on May 12, 2011 and is headquartered in Victoria, Canada.

Eupraxia Pharmaceuticals Inc

EPRX Stock On Retail Radar After Strong Remission Data In Digestive Disease Trial

Equity

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$7.46
Prev Close	$7.57
Open	$7.57
Dividend Yield	0.00%
50-Day Moving Average	$7.47
Beta	0.68
Avg. Volume	647,561.29
PE Ratio	-7.58

52-Week High	$9.32
52-Week Low	$5.25
Market Capitalization	$491.66M
EPS (Annual)	-$1.03
Price to Book	4.80
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info

EPRX Fundamentals